All the Drug Class Drugs
Antithrombotic Agent. Defibrotide 80 mg/ml. VIAL (Concentrat. for sol. for infus.): The recomm. dose is 6.25 mg/kg bdy wt. every 6 hrs. (25 mg/kg/d).
There is limited effic. and safet. data on doses above this level and consequen. it is not recom. to incr. the dose above 25 mg/kg/d.
The tmt. should be admin. for a min. of 21 d. and cont. until the sympt. and signs of sev. VOD resolve. See lit.
Tmt. of sev. hepat. veno-occlusive dis. (VOD) also known as sinusoid. obstruct. syndr. (SOS) in haematopoietic stem-cell transplantat. (HSCT) ther.
It is indicated in adult. and in adolesc., child. and infant. over 1 mnth. of age.
C/I: Hypersens. Concom. use of thrombolytic ther.
Antithrombotic Agent, Direct Factor Xa Inhibitor. Edoxaban 15 mg , 30 mg , 60 mg. FC tab.: 10/28/30X15/30/60 mg.edoxaban
Prevent. of stroke and syst. embol. in adlt pts with nonvalv. atrial fibrill (NVAF) with risk factors, such as congest. HF, HyperT, age ≥ 75 years, diab. mell., prior stroke or trans. isch. attack (TIA).
Tmt of deep vein thromb. (DVT) and pulm. embol. (PE), and
prevent. of recurr. DVT and PE in adults
C/I: Hypersens.
Clinic. sign. act. bleeding.
Hepatic dis. assoc. with coagulopathy and clin. relev. bleeding risk.
Lesion or condit., with a sign. risk for major bleed. such as curr. or recent GI ulcerat., malign. neopl. at high risk of bleed., recent brain or spinal inj., recent brain, spinal or ophth. surg., recent intracranial haemorrh., known or susp. oesophageal varices, arteriovenous malform., vasc. aneurysms or major intraspinal or intracerebr. vasc. abnorm.
Uncontroll. sev. hypert.
Concom. tmt with other anticoag. e.g. UFH, LMWH (enoxaparin, dalteparin, etc.), heparin deriv. (fondaparinux, etc.), oral anticoag. (warfarin, dabigatran etexilate, rivaroxaban, apixaban etc.) except under spec. circumst. of switching oral anticoag. ther. or when UFH is given at doses to maintain an open ctral ven. or arter. catheter.
Pregn. and breast-feed.
Pregn. and breast-feed.
